Ajinomoto Pharmaceuticals Obtains the Marketing Approval of Antihypertensive Agent “ATELEC® Tab. 20”, a Long-acting Calcium Channel Blocker

Ajinomoto Pharmaceuticals Co., Ltd. ("Ajinomoto Pharmaceuticals") (President, Takashi Nagamachi; Headquarters, Tokyo, Japan) obtained as of August 15, 2013 the marketing approval of antihypertensive agent “ATELEC® Tab. 20” indicated for treatment of hypertension.

ATELEC® is a long-acting calcium channel blocker (hereinafter, “Ca channel blocker”) that effectively lowers blood pressure by a once-daily dose, and cilnidipine is the active ingredient of ATELEC®. ATELEC® blocks not only L-type but also N-type calcium channels and inhibits blood pressure elevation due to sympathetic nerve hyperactivity as well as suppresses heart rate increase that occurs when blood pressure falls. In a cohort clinical study with patients who have hypertension and also are suffering from chronic kidney disease (CARTER Study), ATELEC® has been proven to have kidney protective effects. ATELEC® is available in the Japan market under the brand name of “ATELEC® Tab. 5”, “ATELEC® Tab. 10” distributed by Mochida Pharmaceutical Co., Ltd. (President, Naoyuki Mochida; Headquarters, Tokyo, Japan). “ATELEC® Tab. 20” will come onto the market by the same distributor once included in the National Health Insurance drug price list.

In treatment of hypertension, combination use of different agents that have different action mechanisms is common. In addition, there are many patients who take other medicines concomitantly with antihypertensive agents. Ajinomoto Pharmaceuticals expects that reduction in the number of dosing tablets by ATELEC® Tab. 20 can reduce the number of tablets that patients should take and this will contribute to treatment and increase of patient’s Quality of Life in medication.

Ajinomoto Pharmaceuticals is committed to a healthier and better quality of life of each individual patient through practice of “For Your Quality Of Life” to realize wishes of patients and medical practitioners.

-end-

<More Information>

<Indication and dosing regimen of ATELEC®>

<table>
<thead>
<tr>
<th>Brand name</th>
<th>“ATELEC® Tab. 5”, “ATELEC® Tab. 10” and “ATELEC® Tab. 20”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonproprietary name</td>
<td>Cilnidipine</td>
</tr>
<tr>
<td>Indication</td>
<td>Hypertension</td>
</tr>
<tr>
<td>Dosing regimen</td>
<td>Normally once daily 5 to 10 mg of cilnidipine after breakfast orally for adult patient. The dose can be increased or reduced according to the age and symptoms. If the above dose is not effective enough, the dose can be increased to 20 mg once daily. For severe hypertension, 10 to 20 mg of cilnidipine orally once daily after breakfast.</td>
</tr>
</tbody>
</table>
【Contact】
Ajinomoto Pharmaceuticals Co., Ltd.
Corporate Planning Dept.
TEL: +81-(0)3-6280-9802 FAX: +81-(0)3-6280-9912